PMC10469228_01
(a) Lung FNA, highly cellular smears from aspirate (Diff Quik stain, low power). (b) Cohesive cluster of malignant cells with pleomorphic nuclei and vacuolated cytoplasm (Diff Quik stain, high power). (c and d) groups of malignant cells with atypical nuclei and vacuolated cytoplasm (H&E stain, low and intermediate power).
10.1177_2050313X231196663-fig1.jpg
PMC10469228_01_10.1177_2050313X231196663-fig1.jpg
fig1-2050313X231196663
Biopsies revealed positive malignant cells characteristic of metastatic pulmonary adenocarcinoma at lymph node stations 4, 4 L and 4 R. (Figures 1 and 2).
Immunohistochemical stains. (a and b) The neoplastic cells display positive cytoplasmic/membranous pankeratin stain (AE1/AE3, intermediate and high power). (c) Napsin A is positive with granular cytoplasmic stain (Napsin A, high power), (d) Thyroid Transcription Factor 1 ( TTF-1) is expressed as strong and diffuse nuclear staining (TTF-1, high power).
10.1177_2050313X231196663-fig2.jpg
PMC10469228_01_10.1177_2050313X231196663-fig2.jpg
fig2-2050313X231196663
Biopsies revealed positive malignant cells characteristic of metastatic pulmonary adenocarcinoma at lymph node stations 4, 4 L and 4 R. (Figures 1 and 2).
(a) Chest CT before Osimertinib initiation. (b) Chest CT 6 months after Osimertinib initiation.. CT, computed tomography.
10.1177_2050313X231196663-fig3.jpg
PMC10469228_01_10.1177_2050313X231196663-fig3.jpg
fig3-2050313X231196663
No further new sites of disease were identified (Figure 3(a) and (b)).